NCT02626338 2023-12-20
Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML
Arog Pharmaceuticals, Inc.
Phase 1/2 Completed
Clinical Trials
9 trialsNCT02298166 2021-10-06
Study of Crenolanib in Combination With Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Activating FLT3 Mutations
University of Ulm
Phase 3 Terminated
NCT02847429 2021-01-22
Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST
Arog Pharmaceuticals, Inc.
Phase 3 Unknown
NCT02626364 2020-07-20
Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification
Arog Pharmaceuticals, Inc.
Phase 2 Completed
NCT01229644 2018-07-05
Study of Crenolanib, a Selective and Potent Inhibitor of PDGFR, for the Treatment of Adult Gliomas
Arog Pharmaceuticals, Inc.
Phase 2 Terminated
NCT02270788 2017-10-03
Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies
St. Jude Children's Research Hospital
Phase 1 Completed
NCT01393912 2017-04-26
PDGFR Inhibitor Crenolanib in Children/Young Adults With Diffuse Intrinsic Pontine Glioma or Recurrent High-Grade Glioma
St. Jude Children's Research Hospital
Phase 1 Completed
NCT00386555 2012-08-09
A Phase 2 Study in Patients With Advanced Non-Small Cell Lung Cancer Using New Agents With and Without Docetaxel.
Arog Pharmaceuticals, Inc.
Phase 2 Withdrawn
NCT00949624 2012-01-19
CP-868,596 And CP-868,596 Plus AG-013736 In Combination With Docetaxel In Advanced Solid Tumors
Arog Pharmaceuticals, Inc.
Phase 1 Completed